Media & news

Cancellation of publicly held Nobel Biocare shares and de-listing from SIX Swiss Exchange as of June 10, 2015

Zurich, Switzerland, June 2, 2015 – By decision dated May 13, 2015, the Commercial Court of the Canton of Zurich cancelled all registered shares of Nobel Biocare Holding AG not directly or indirectly held by Danaher Corporation based on article 33 of the Federal Act on Stock Exchanges and Securities Trading.

Holders of cancelled shares will be paid cash compensation in the amount of CHF 17.10 for each cancelled share, corresponding to the offer price paid by Danaher Corporation in its public tender offer for all publicly held shares of Nobel Biocare Holding AG. It is expected that the compensation will be paid on or around June 16, 2015.

By decision dated [June 1, 2015], SIX Exchange Regulation definitively approved the de-listing of the registered shares of Nobel Biocare Holding AG from SIX Swiss Exchange as of June 10, 2015. The last trading day of the registered shares of Nobel Biocare Holding AG will be June 9, 2015.

Nobel Biocare is a world leader in the field of innovative implant-based dental restorations. The company’s portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician® and DTX Studio™) and biomaterials (creos). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland. Production takes place at six sites located in the United States, Sweden, Japan and Israel. Products and services are available in over 80 countries through subsidiaries and distributors.